Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
RECRUITING
NCT06747260
EARLY_PHASE1

Feasibility and Safety of Intranasally Administered Breast Milk in HIE

Sponsor: Semmelweis University

View on ClinicalTrials.gov

Summary

This is a prospective intervention single center study to evaluate the feasibility and safety of intranasal breast milk in hypoxic-ischaemic encephalopathic neonates receiving therapeutic hypothermia.

Official title: Feasibility and Safety of Intranasal Breast Milk in Hypoxic-ischaemic Encephalopathy

Key Details

Gender

All

Age Range

Any - 48 Hours

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2024-11-22

Completion Date

2030-01-01

Last Updated

2025-05-22

Healthy Volunteers

No

Conditions

Hypoxic Ischaemic Encephalopathy (HIE)Hypoxic Ischemic Encephalopathy of NewbornNeonatal EncephalopathyNeonatal Hypoxic Ischemic EncephalopathyBrain InjuryPerinatal AsphyxiaPerinatal Asphyxia , Moderate to Severe HIE

Interventions

BIOLOGICAL

Intranasal breast milk

Neonates with hypoxic-ischemic encephalopathy receive their own-mother's fresh breast milk intranasally, starting from the first 48 hours of life and continuing for 28 days. Dose: 2 times daily, 0.4 ml in each nostril (15 minutes apart).

Locations (1)

Division of Neonatology, Pediatric Center, Semmelweis University, Budapest, Hungary

Budapest, Hungary